Drugs / HPP404
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01540864 | May 2012 → May 2013 | obesity disorder | High Point Pharmaceuticals, LLC. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HPP404 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01540864 ↗ |
| Route | Oral | “Administered orally once daily for 26 weeks” NCT01540864 ↗ |